Importer of Controlled Substances Application: Sharp Clinical Services, LLC, 48509-48510 [2022-16991]
Download as PDF
<![CDATA[
48509
Federal Register / Vol. 87, No. 152 / Tuesday, August 9, 2022 / Notices
Controlled substance
Alfentanil .........................................................................................................................................................................................
Remifentanil ....................................................................................................................................................................................
Sufentanil ........................................................................................................................................................................................
Carfentanil ......................................................................................................................................................................................
Tapentadol ......................................................................................................................................................................................
The company plans to import the
listed controlled substances for the
manufacturing of analytical reference
standards and distribution to their
research and forensic customers. No
other activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–16994 Filed 8–8–22; 8:45 am]
BILLING CODE P
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on July 7, 2022, Experic
LLC, 2 Clarke Drive, Cranbury, New
Jersey 08512–3619, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Controlled substance
DEPARTMENT OF JUSTICE
Psilocybin ........................
Psilocyn ...........................
Drug
code
Schedule
7437
7438
I
I
Drug Enforcement Administration
[Docket No. DEA–1064]
Bulk Manufacturer of Controlled
Substances Application: Experic LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Experic LLC has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 11, 2022. Such
persons may also file a written request
for a hearing on the application on or
before October 11, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
jspears on DSK121TN23PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:04 Aug 08, 2022
Jkt 256001
The company plans to bulk
manufacture the listed controlled
substances for drug codes 7437
(Psilocybin) and 7438 (Psilocyn),
planning on germinating mushrooms to
be harvested and freeze dried in form of
powder to be filled into capsules for use
in clinical studies.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–17012 Filed 8–8–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1042]
Importer of Controlled Substances
Application: Sharp Clinical Services,
LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Frm 00059
Fmt 4703
Sfmt 4703
9737
9739
9740
9743
9780
II
II
II
II
II
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 8, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 8, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 23, 2022, Sharp
Clinical Services, LLC, 2400 Baglyos
Circle, Bethlehem, Pennsylvania 18020–
8024, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUMMARY:
PO 00000
Schedule
DATES:
Controlled substance
Sharp Clinical Services, LLC
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
Drug
code
5-Methoxy-N-Ndimethyltryptamine.
Drug
code
7431
Schedule
I
The company plans to import the
listed control substances for clinical
E:\FR\FM\09AUN1.SGM
09AUN1
48510
Federal Register / Vol. 87, No. 152 / Tuesday, August 9, 2022 / Notices
DEPARTMENT OF JUSTICE
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on June 24, 2022, VHG
Labs, DBA LGC Standards, 3 Perimeter
Road, Manchester, New Hampshire
03103–3341 applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
Drug Enforcement Administration
Controlled substance
trials. No other activity for this drug
code is authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–16991 Filed 8–8–22; 8:45 am]
BILLING CODE P
Drug
code
Schedule
[Docket No. DEA–1053]
Importer of Controlled Substances
Application: VHG Labs, DBA LGC
Standards
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
VHG Labs, DBA LGC
Standards has applied to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 8, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 8, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
jspears on DSK121TN23PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:04 Aug 08, 2022
Jkt 256001
Mephedrone (4-Methyl-Nmethylcathinone).
2,5Dimethoxyamphetamine.
Bufotenine ................
Psilocybin .................
Alphamethandol ........
Amphetamine ...........
1248
I
7396
I
7433
7437
9605
1100
I
I
I
II
The company plans to import the
listed controlled substances for
distribution for analytical testing
purposes. No other activity for this drug
code is authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–16996 Filed 8–8–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
listed below for further drug
information.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 8, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 8, 2022.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on February 3, 2022,
Stepan Company, 100 West Hunter
Avenue, Maywood, New Jersey 07607–
1021, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
[Docket No. DEA–998]
Importer of Controlled Substances
Application: Stepan Company
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Stepan Company has applied
to be registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
SUMMARY:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Coca Leaves ............
Drug
code
9040
Schedule
I
The company plans to import the
listed controlled substance in bulk for
the manufacture of controlled
substances for distribution to its
customers. No other activity for this
drug code is authorized for this
registration. No other activity for this
drug code is authorized for this
registration.
E:\FR\FM\09AUN1.SGM
09AUN1
]]>Agencies
[Federal Register Volume 87, Number 152 (Tuesday, August 9, 2022)]
[Notices]
[Pages 48509-48510]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16991]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1042]
Importer of Controlled Substances Application: Sharp Clinical
Services, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Sharp Clinical Services, LLC has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
September 8, 2022. Such persons may also file a written request for a
hearing on the application on or before September 8, 2022.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 23, 2022, Sharp Clinical Services, LLC, 2400
Baglyos Circle, Bethlehem, Pennsylvania 18020-8024, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
5-Methoxy-N-N-dimethyltryptamine....... 7431 I
------------------------------------------------------------------------
The company plans to import the listed control substances for
clinical
[[Page 48510]]
trials. No other activity for this drug code is authorized for this
registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-16991 Filed 8-8-22; 8:45 am]
BILLING CODE P
